Insights On Drug Development

31. Overcoming Challenges To High-Concentration Formulation Development 3/25/2025

    Explore how the S-HiCon™ platform optimizes high-concentration therapeutic antibody formulations, overcoming stability and manufacturability challenges to deliver safe, effective therapies.

32. Bora Pharmaceuticals: A Future Focused CDMO 3/25/2025

    Specializing in formulation development, clinical and commercial manufacturing, and advanced packaging solutions, we bring expertise across a diverse range of dosage forms.

33. Shifting Drug Development With Advanced Analytical Characterization 3/24/2025

    Explore the advancing mass spectrometry, biophysical characterization, automated sample preparation, and high throughput analytics required to deliver medicines in a safe, compliant, and efficient manner.

34. Rapid Delivery Of Toxicological Study Material: Accelerating Development 3/19/2025

    Explore key strategies and technologies designed to address the analytical considerations and material flows to facilitate the rapid delivery of toxicological material.

35. One-Step SAR: Using High-Content Imaging To Drive Small Molecule Protein Degraders From Hit To Lead 3/18/2025

    Discover Curia’s cost-effective high-content immunofluorescence workflow using the Revvity Opera Phenix™ system to efficiently identify small molecule protein degraders with rich, multi-dimensional data.

36. Analytical Method Release And Stability Platform For RNA Drug Substance 3/14/2025

    We offer comprehensive analytical support across the R&D space, including method development, validation, process characterization, in-process testing, process validation, and GMP release testing.

37. Supply-Chain Statistics And Realistic Outsourcing Options 3/12/2025

    Kishore Hotha, President, Dr. Hotha’s Life Sciences, provides some telling stats that should inform outsourcing decision-making in the coming months… and perhaps years.

38. Remind Me: Why Are We At Biotech War With China? 3/12/2025

    It’s hard to focus on the issues that precipitated the challenges and proscribed solutions to so much of our supply chain being in China. IP was (and should be) at the center of the discussion.

39. Good 'Supplier Hygiene' Before And After COVID And The BIOSECURE Act 3/12/2025

    Can you recall the fundamentals of outsourcing development and manufacturing five or 10 years ago, if you were in the industry then? Our panel can, and it’s instructive to take the trip back in time.

40. Smaller Biotechs Take Bigger Hits 3/12/2025

    Our panel of experienced biopharma executives explain the different effects on trade wars or supply-chain disruptions with Big Pharma and smaller drug development organizations.